Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis.
CAR T cell therapy
antifungal
hematopoietic cell transplantation (HCT)
immunosuppression
invasive fungal infection
mold
prophylaxis
risk factors
yeast
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
18
05
2023
revised:
26
06
2023
accepted:
05
07
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
(1) Background: Autologous, allogeneic hematopoietic cell transplantation (HCT) and other cellular therapies, including CAR T cell and gene therapy, constitute a cornerstone in the management of various benign and malignant hematological disorders. Invasive fungal infections (IFD) remain a significant cause of morbidity and mortality in HCT recipients. Therefore, we investigated the prevalence and risk factors of IFD following HCT and other cellular therapies in an era of novel antifungal prophylaxis. (2) Methods: In this study, we retrospectively enrolled adult HCT recipients who were treated at our JACIE-accredited center according to standard operating procedures over the last decade (2013-2022). (3) Results: 950 patients who received cellular therapies were studied. None of the 19 CAR T cell and neither of the two gene therapy recipients developed IFD whereas 3/456 autologous HCT recipients who suffered from primary refractory/relapsed lymphomas presented with probable IFD. Overall, 11 patients who received allogeneic HCT experienced probable IFD, possible IFD was found in 31/473, and IFD was proven in 10/473. A second IFD episode was present in three patients. Four-year OS was significantly lower in proven compared to probable IFD (
Identifiants
pubmed: 37444639
pii: cancers15133529
doi: 10.3390/cancers15133529
pmc: PMC10341183
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Infect Dis. 2000 Jun;30(6):851-6
pubmed: 10852735
Biol Blood Marrow Transplant. 1999;5(2):55-68
pubmed: 10371357
Clin Infect Dis. 2005 Jan 1;40(1):89-99
pubmed: 15614697
Clin Infect Dis. 2007 Nov 1;45(9):1161-70
pubmed: 17918077
Med Mycol. 2005 May;43 Suppl 1:S49-58
pubmed: 16110792
Open Forum Infect Dis. 2020 Apr 09;7(5):ofaa121
pubmed: 32432149
Clin Immunol. 2021 Jul;228:108731
pubmed: 33892201
Blood. 1999 Jan 15;93(2):467-80
pubmed: 9885208
Infect Dis Clin North Am. 2010 Jun;24(2):257-72
pubmed: 20466269
Clin Infect Dis. 2018 Oct 30;67(10):1621-1630
pubmed: 29860307
J Clin Med. 2020 May 31;9(6):
pubmed: 32486396
BMC Infect Dis. 2015 Dec 29;15:584
pubmed: 26715563
Clin Infect Dis. 2002 Apr 1;34(7):909-17
pubmed: 11880955
J Infect. 2016 Nov;73(5):496-505
pubmed: 27394404
J Zhejiang Univ Sci B. 2015 Sep;16(9):796-804
pubmed: 26365122
Blood Adv. 2022 Aug 23;6(16):4821-4830
pubmed: 35802461
Semin Oncol. 1993 Oct;20(5 Suppl 6):80-7
pubmed: 8211220
Ann Hematol. 2018 Oct;97(10):1987-1994
pubmed: 29869673
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Expert Rev Hematol. 2010 Jun;3(3):285-99
pubmed: 20871781
Curr Opin Infect Dis. 2019 Dec;32(6):538-545
pubmed: 31688198
Open Forum Infect Dis. 2017 Mar 22;4(2):ofx050
pubmed: 28491889
N Engl J Med. 2014 Sep 4;371(10):895-905
pubmed: 25184862
J Antimicrob Chemother. 2018 Dec 1;73(12):3221-3230
pubmed: 30085172
Clin Infect Dis. 2021 Mar 12;72(Suppl 2):S79-S88
pubmed: 33709131
Biol Blood Marrow Transplant. 2015 Jun;21(6):1117-26
pubmed: 25840339
Med Mycol. 2018 Nov 1;56(8):917-925
pubmed: 29267891
Transpl Infect Dis. 2014 Feb;16(1):90-7
pubmed: 24256514
Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):658-666
pubmed: 28716402
Biol Blood Marrow Transplant. 2013 Aug;19(8):1190-6
pubmed: 23747459
Curr Opin Oncol. 2005 Mar;17(2):89-92
pubmed: 15725910
Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238
pubmed: 19747629
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Bone Marrow Transplant. 2009 Oct;44(8):483-7
pubmed: 19861982
Front Pediatr. 2021 Jul 27;9:634449
pubmed: 34386464
Clin Infect Dis. 2018 Aug 1;67(4):533-540
pubmed: 29481659
Blood. 2018 Jan 4;131(1):121-130
pubmed: 29038338
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Transplant. 2017 Apr;31(4):
pubmed: 28224660
Bone Marrow Transplant. 2009 Sep;44(6):361-70
pubmed: 19308042
Am J Hematol. 2017 Dec;92(12):1303-1310
pubmed: 28850704
Biol Blood Marrow Transplant. 2017 Mar;23(3):445-451
pubmed: 27914967
Eur J Haematol. 2004 Sep;73(3):174-8
pubmed: 15287914
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Intern Med J. 2021 Nov;51 Suppl 7:67-88
pubmed: 34937140
Clin Infect Dis. 2010 Apr 15;50(8):1091-100
pubmed: 20218877
Blood Cancer J. 2020 Aug 5;10(8):79
pubmed: 32759935
J Fungi (Basel). 2021 Oct 31;7(11):
pubmed: 34829213
J Antimicrob Chemother. 2016 Mar;71(3):718-26
pubmed: 26612870
Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33
pubmed: 31419568
Blood Rev. 2019 Mar;34:34-44
pubmed: 30467067
Bone Marrow Transplant. 2005 Oct;36(7):621-9
pubmed: 16044133
Int J Hematol. 2012 Dec;96(6):748-57
pubmed: 23111539
Infection. 2021 Apr;49(2):215-231
pubmed: 32979154
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607